Connor, Clark & Lunn Investment Management Ltd. Avidity Biosciences, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 217,025 shares of RNA stock, worth $6.39 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
217,025
Previous 5,513
3836.6%
Holding current value
$6.39 Million
Previous $225,000
4329.78%
% of portfolio
0.05%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RNA
# of Institutions
254Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$313 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$272 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$254 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$240 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$207 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.54B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...